Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI MeetingNEW HOPE, Pa., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two presentations at the 2024 Innovation in Cardiology Intervention (“ICI”) meeting in Tel Aviv, Israel. The presentations will provide insights on the ongoing BACKBEAT global pivotal study, as well as an overview of the novel mechanism of action of AVIM therapy and supporting clinical evidence for the treatment of uncontrolled hypertension in patients indicated for a dual-chamber pacemaker. The presentations will be part of a broad scientific program of important developments in cardiology, in a session focused on “Device-Based Hypertension Treatment.”
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare ConferenceNEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY from December 3-5, 2024.
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business UpdateNEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update.
Orchestra BioMed to Participate in Jefferies London Healthcare ConferenceNEW HOPE, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies London Healthcare Conference being held in London, UK from November 19-21, 2024.
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business UpdateNEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update.
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of DirectorsNEW HOPE, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of John Mack to its Board of Directors, effective as of July 29, 2024. Mr. Mack brings over 30 years of medical device, healthcare technology, and finance experience to the Company. Mr. Mack most recently served as President of Cardiac Surgery at Medtronic plc., where he successfully led the division to market leadership. During his tenure at Medtronic, he also served as Vice President & General Manager, Extracorporeal Therapies and Vice President, Business Development, Strategy & Portfolio Management where he led the business development operations for the coronary and structural heart business, a $3.2B global enterprise with over 12,000 employees.
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024NEW HOPE, Pa., June 04, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced further details on its in-person R&D day at the Lotte New York Palace Hotel on Tuesday, June 11, 2024, at 10:00 AM ET. To register, click here.
Orchestra BioMed to Participate in Jefferies Global Healthcare ConferenceNEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024.
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business UpdateNEW HOPE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update.
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued PatentsNEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the patent estate related to AVIM Therapy has reached 110 patents worldwide. The most recent patent was issued today, April 30, 2024.
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced it will host an in-person R&D day at the Lotte New York Palace Hotel on Tuesday, June 11, 2024 at 10:00 AM ET. To register, click here.
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business UpdateNEW HOPE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of DirectorsNEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of David Pacitti to its Board of Directors, effective as of March 26, 2024. Mr. Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. Prior to joining Siemens Healthineers, he was Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular, overseeing the company’s business in North America. As a member of the Senior Executive Staff, he worked with the CEO, CFO, and Research & Development team on business development initiatives and played pivotal roles in key launches, including Abbott Vascular’s first drug-eluting stent and structural heart franchise.
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual MeetingNEW HOPE, Pa., March 13, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced two oral presentations were given at the Cardiovascular Research Technologies (“CRT”) 2024 Meeting in Washington, D.C. One presentation featured new preclinical pharmacokinetic (“PK”) data on Virtue® Sirolimus AngioInfusion Balloon (“SAB”), a novel drug-eluting balloon angioplasty system designed to deliver a proprietary, extended-release formulation of sirolimus, SirolimusEFR™ to the vessel wall during balloon angioplasty without any coating on the balloon surface. A second presentation featured recently reported clinical data on atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT), an investigational therapy delivered via standard dual-chamber pacemakers designed to immediately, substantially and persistently lower blood pressure. The AVIM presentation also outlined the design of the currently enrolling BACKBEAT global pivotal study evaluating AVIM therapy in hypertensive pacemaker patients in collaboration with Medtronic.
Orchestra BioMed to Participate in Upcoming Investor ConferencesNEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple conferences throughout March 2024.
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker PatientsNEW HOPE, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of new clinical data from a pressure-volume (“PV”) loop study of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT™) in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medication. These data demonstrate the favorable impact of AVIM therapy compared to standard right ventricular (RV) pacing on systolic blood pressure and overall cardiac function when delivered using both conduction system andstandard pacing lead locations. The PV loop study was conducted at Na Homolce Hospital in Prague by Prof. Petr Neužil, M.D. and the data were featured in an oral presentation at the Technology and Heart Failure Therapeutics (“THT”) 2024 Meeting by Prof. Karl-Heinz Kuck, M.D., Medical Director at LANS Cardio Hamburg.
Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 YearsNEW HOPE, Pa., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of new data demonstrating the long-term effect of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT™) on generating clinically-meaningful reductions in 24-hour ambulatory systolic blood pressure (“aSBP”) in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications. The data were presented by Avi Fischer, M.D., Senior Vice President of Medical Affairs and Innovation of Orchestra BioMed in a scientific session at the Innovation in Cardiovascular Interventions (“ICI”) 2024 Meeting.
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business UpdateNEW HOPE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2023 financial results and provided a business update.
Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker PatientsNEW HOPE, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the U.S. Food and Drug Administration (“FDA”) granted approval of an investigational device exemption (“IDE”) to initiate the global pivotal BACKBEAT (BradycArdia paCemaKer with atrioventricular interval modulation for Blood prEssure treAtmenT) study evaluating the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT™) for treating hypertensive patients who are indicated for a dual-chamber cardiac pacemaker.
Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business UpdateNEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2023 financial results and provided a business update.
Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent RestenosisNEW HOPE, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the U.S. Food and Drug Administration (the “FDA”) granted investigational device exemption (“IDE”) approval with conditions to initiate the Virtue ISR-US pivotal study evaluating the efficacy and safety of Virtue® SAB for the treatment of patients with coronary ISR. Virtue SAB is a novel AngioInfusion balloon for the treatment of artery disease that is designed to enable protected delivery of SirolimusEFR™, a proprietary, investigational, extended release formulation of sirolimus, to the artery during balloon angioplasty without the need for balloon coating or a permanent implant.
Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell IndexesNEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that it is set to join the broad-market Russell 3000® Index, the small-cap Russell 2000® Index, and the Russell Microcap® index at the conclusion of the 2023 Russell indexes annual reconstitution, effective after the U.S. market opens today, June 26, 2023, according to a preliminary list of additions posted May 19, 2023.
Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial OfficerBill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly created Executive Vice President (EVP) of Corporate Development and Strategy role
Orchestra BioMed to Present at the Jefferies Global Healthcare ConferenceNEW HOPE, Pa., June 01, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 7-9, 2023.
Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business UpdateNEW HOPE, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2023 financial results and provided a business update.
Orchestra BioMed to Present at Upcoming Investor ConferencesNEW HOPE, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at Oppenheimer’s 33rd Annual Healthcare Conference, which is taking place virtually from March 13-15, 2023, and the Barclays Global Healthcare Conference, which is taking place in Miami, FL, from March 14-16, 2023.
Orchestra BioMed Strengthens Senior Leadership TeamAvi Fischer, M.D., joins as SVP, Medical Affairs and Innovation; J.C. Simeon assumes role of SVP, Quality
